Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease [PDF]
, 2014 Trimetazidine is a cytoprotective drug whose cardiovascular effectiveness, especially in patients with stable ischemic heart disease, has been the source of much controversy in recent years; some have gone so far as to treat the medication as a ‘placebo ...
Jacek Rysz +2 more
core +1 more source
BMJ Open Diabetes Research & Care, 2022 Introduction Insulin resistance (IR) plays a key role in the pathogenesis and clinical course of patients with multiple metabolic diseases and diabetes.
Wenliang Zhang +8 more
semanticscholar +1 more source
Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure [PDF]
, 2017 Despite significant improvements in morbidity and mortality with current evidence-based pharmaceutical-based treatment of heart failure (HF) over the previous decades, the burden of HF remains high.
Li, Mann, Morrow, Murray, Sabbah, Zhang
core +2 more sources
Bioengineered, 2022 Trimetazidine (TMZ) has been used extensively to treat coronary artery disease and to reduce fibrosis. Liver fibrosis is a reversible process. However, the impacts of TMZ on liver fibrosis triggered by CCl4 and on hepatic stellate cells in liver fibrosis
Wenwen Ding +5 more
semanticscholar +1 more source
Expert consensus document: A 'diamond' approach to personalized treatment of angina. [PDF]
, 2017 In clinical guidelines, drugs for symptomatic angina are classified as being first choice (β-blockers, calcium-channel blockers, short-acting nitrates) or second choice (ivabradine, nicorandil, ranolazine, trimetazidine), with the recommendation to ...
A Abbate +101 more
core +1 more source
АТP as the marker of power exchange condition at the experimental ischemia of the myocardium due to metabolic drugs introduction [PDF]
, 2016 For the purpose of definition of an adequate marker of a power exchange condition at the experimental ischemia of the myocardium due introduction of metabolic drugs, the experimental research on 60 rats-males of Wistar line has been spent.
Gorbach, T. V. +3 more
core +2 more sources
Reviews in Cardiovascular Medicine, 2021 Trimetazidine has been reported to benefit patients with heart failure (HF) and angina. The impact of trimetazidine on non-ischemic HF remains unclear.
Chengchen Zhao +3 more
doaj +1 more source
Trimetazidine and COVID-19-induced acute cardiac injury: a missed key
International Journal of Clinical Pharmacy, 2022 for entry into the host cells [2]. SARS-CoV-2 spike protein binds to ACE2 causing down-regulation of this receptor [2]. ACE2 has a protective effect on cardiomyocytes by reducing angiotensin II (AngII)-induced cardiac fibrosis, hypertrophy, and diastolic
H. Al-kuraishy +3 more
semanticscholar +1 more source
Sirtuin 1 in rat orthotopic liver transplantation: An IGL-1 preservation solution approach [PDF]
, 2015 © The Author(s) 2015. AIM: To investigate the possible involvement of Sirtuin 1 (SIRT1) in rat orthotopic liver transplantation (OLT), when Institute Georges Lopez 1 (IGL-1) preservation solution is enriched with trimetazidine (TMZ).
Abdennebi, Hassen B. +8 more
core +2 more sources
Triple antianginal combinations in the treatment of elderly and senile patients with stable angina [PDF]
Терапевтический архив, 2016 Aim. To compare the efficiency and safety of antianginal therapy (AAT) using a combination of bisoprolol, ivabradine, and trimetazidine or ranolazine in elderly and senile patients with stable angina. Subjects and methods. The study enrolled 107 patients
S G Kanorskii, N V Smolenskaya
doaj +1 more source